|Slideshows|November 5, 2019

Reduce COPD Exacerbations with Combination Therapy

Combination therapy found to reduce COPD exacerbations, no exacerbation reduction with β-blockers, plus 3 more must-read studies.

Combination therapy reduces exacerbations, no exacerbation reduction with beta-blockers, care program did harm rather than good-these are some of the latest developments in chronic obstructive pulmonary disease (COPD) research. Scroll through the slides below to find concise summaries of key points for clinical practice.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Related to this article

November 13th, 2026

Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial

AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.

November 13th, 2026

American Cancer Society Updates Prostate Cancer Screening Guidelines

The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.

November 12th, 2026

Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain

Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.

November 11th, 2026

FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.

November 10th, 2026

Survodutide Meets Cardiovascular Safety Endpoint in Phase 3 Obesity Trial

Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.

November 5th, 2026

Evolocumab Tied to 20% Lower Risk of Myocardial Infarction vs Ezetimibe in Real-World Study

Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.

November 4th, 2026

FDA Clears 15-Minute Blood Test to Help Distinguish Bacterial From Viral Infections

The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.

November 3rd, 2026

Mediterranean Diet Linked to Lower Odds of Adult Acne in New Study

Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.